AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05558397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Oral morphine)
Description: Oral administration of morphine, pregabalin or duloxetin
Study NCT03504618 — intervention group
Intervention type: DRUG
Intervention: FOLFOXIRI
Description: Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day
Study NCT03383991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse Total Shoulder Arthroplasty
Study NCT03383991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Study NCT01619865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC PET/CT
Description: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
Study NCT01494818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide-based contact lens care system
Study NCT03766477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: All participants slept for one night in a sleep laboratory for PSG recording. The data will be confirmed by an otorhinolaryngology certified by the Brazilian Association of Sleep Disorders
Study NCT04896424 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cryoballoon-based pulmonary veins isolation
Description: A cryoballoon is introduced to the LA via a steerable sheath following a single transseptal puncture. The balloon is advanced toward the PV ostium and inflated. PV occlusion is documented by the injection of contrast. Optimal vessel occlusion is assumed when the PV showes complete contrast retention without any backflow to the atrium. The freezing time is chosen between 180 and 240s and left at the operator's discretion, along with a decision if to follow with a bonus-freeze cycle. The application is aborted and the cryoballoon is repositioned in the case of ineffective cooling or when the nadir temperature decreases \< -60°C, to avoid excessive cooling. In cases where a real-time recording of PV potentials is available a short time-to-isolation\<60s resultes in a single 180s freeze cycle. CBA always startes from the left upper PV (LUPV) followed by the left lower PV (LLPV).
Study NCT03480932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C
Study NCT03480932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C
Study NCT03480932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alfa-2a
Description: Antiviral agent used for the treatment of hepatitis C
Study NCT00254826 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: YF-VAX® plus saline
Description: YF-VAX® plus saine
Study NCT01494818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHMB-containing contact lens solution
Study NCT01494818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Description: Contact lenses identical to habitual prescription worn per usual replacement regimen
Study NCT01494818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft contact lenses
Description: Contact lenses identical to habitual prescription worn per usual replacement regimen
Study NCT03215537 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive intervention
Description: preoperative and postoperative exercise program
Study NCT02240017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
Study NCT00254826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 17D YF Vaccine plus Ig,
Description: 17D YF Vaccine plus Ig, one vaccine on day 0
Study NCT04654637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Exercise Strategies
Description: Multiple Interactive with Nutrition and Exercise Strategies
Study NCT02240017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fractionated Cisplatin
Description: Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
Study NCT02240017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
Study NCT02240017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
Study NCT02535039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg \* d for application to the third day after surgery
Study NCT02535039 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: The same volume of physiological saline will be given in Placebo group
Study NCT02771821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operative groups based on methodology of problematization
Description: The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months.
Study NCT03711032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization
Study NCT03711032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
Study NCT01569126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY110140
Description: Administered orally as capsules
Study NCT01569126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
Study NCT00791999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870 400mg
Description: 400mg CDP870 given every 2 weeks until Week22 (SC)
Study NCT00791999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870 200mg
Description: 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
Study NCT00791999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870 100mg
Description: 200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
Study NCT00791999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CDP870
Description: given every 2 weeks until Week22 (SC)
Study NCT01572402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bagueutte Cheese Gourmet (Crocodille)
Description: 180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
Study NCT01572402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bagueutte Cheese Gourmet (Crocodille)
Description: 180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
Study NCT02787044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Trivalent Influenza Vaccine
Description: High Dose Trivalent Influenza Vaccine
Study NCT02787044 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Quadrivalent Influenza Vaccine
Description: Standard Dose Quadrivalent Influenza Vaccine
Study NCT02135562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
Study NCT02135562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Material
Description: Receive carbohydrate reintroduction handout
Study NCT02135562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Education
Description: Receive education on nutrition label reading for carbohydrates
Study NCT02135562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight Maintenance
Description: weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
Study NCT02135562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Average score of Obesity and Weight-Loss Quality of Life Questionnaire
Description: Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
Study NCT02247453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening
Description: All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.~Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT.
Study NCT02643264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS 10 Hz targeting the insula
Description: Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session
Study NCT02643264 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation with the same regimen as active treatment
Study NCT01012401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHESS website for lung cancer patient + internet access if needed
Description: The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
Study NCT01012401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHESS website for lung cancer patient + internet access if needed
Description: The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
Study NCT04825405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hand motor coordination in a sitting position after use TipStim Glove
Description: The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
Study NCT04825405 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: hand motor coordination in a sitting position after use TipStim Glove
Description: The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
Study NCT06147349 — intervention group
Intervention type: PROCEDURE
Intervention: Radical or partial nephrectomy
Description: Removal of neoplastic mass either by full kidney excision or by targeted cancer removal
Study NCT04489810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules
Study NCT04489810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules
Study NCT04489810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elevase®
Description: 1 capsule containing 350 mg of Elevase®
Study NCT04489810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DE111®
Description: 1 capsule containing Bacillus subtilis DE111
Study NCT04489810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal A
Description: Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
Study NCT04489810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Meal A
Description: Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
Study NCT04489810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal B
Description: Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
Study NCT01786226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of mifepristone 2.5 mg daily for three months
Description: Experimental: 1
Study NCT01786226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of mifepristone 5 mg daily for three months
Description: Experimental: 2
Study NCT03845231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax(R)
Description: Cohort 1 will receive IM quadrivalent IIV (Flucelvax (R)) at the standard dose of 15 micrograms HA per strain (60 micrograms HA total).
Study NCT03845231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Challenge virus
Description: A dose of 10\^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
Study NCT03845231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Human Challenge virus
Description: A dose of 10\^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
Study NCT01572402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cous-cous sandwich
Description: 235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
Study NCT01969682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
Study NCT01969682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
Study NCT00531219 — intervention group
Intervention type: PROCEDURE
Intervention: Transgastric Appendectomy
Description: The appendix will be removed through an incision in the stomach and pulled out through the mouth
Study NCT00531219 — intervention group
Intervention type: PROCEDURE
Intervention: Transgastric Cholecystectomy
Description: The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
Study NCT01572402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cous-cous sandwich
Description: 235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
Study NCT01572402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McCountry sandwich (McDonald's)
Description: 150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
Study NCT01572402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McCountry sandwich (McDonald's)
Description: 150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
Study NCT00789360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Placebo
Description: Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
Study NCT00219947 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: * T cell subset enumeration~* Serologic reactivity with HIV antigens~* Viral load assays by bDNA, PCR, or RT-PCR~* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~* HIV-1 Resistance Testing
Study NCT00789360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine
Description: Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
Study NCT03139604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
Study NCT03139604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
Study NCT03139604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
Study NCT03139604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
Study NCT03139604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.